Jennifer Doudna

Move to Berkeley

In 2002, she joined her husband, Jamie Cate, at Berkeley, accepting a position as professor of biochemistry and molecular biology. Doudna also gained access to the synchrotron at Lawrence Berkeley National Laboratory for her experiments with high powered x-ray diffraction.

In 2009, she took a leave of absence from Berkeley to work at Genentech to lead discovery research. She left Genentech after two months and returned to Berkeley with the help of colleague Michael Marletta, canceling all of her obligations to study CRISPR.

As of 2023, Doudna was located at the University of California, Berkeley, where she directs the Innovative Genomics Institute, a collaboration between Berkeley and UCSF founded by Doudna to develop genome editing technology and apply it to some of society's greatest problems in human health, agriculture and climate change. Doudna holds the Li Ka Shing Chancellor's Professorship in Biomedicine and Health, and is the chair of the Chancellor's Advisor Committee on Biology. Her lab now focuses on the structure and function of CRISPR-Cas systems, developing new genome editing technology and delivery mechanisms for CRISPR therapeutics, and novel techniques for precisely editing microbiomes.

CRISPR-Cas9 genome editing discovery

Doudna was introduced to CRISPR by Jillian Banfield in 2006 who had found Doudna by way of a Google search, having typed "RNAi and UC Berkeley" into her browser, and Doudna's name came up at the top of the list. In 2012, Doudna and her colleagues made a new discovery that reduces the time and work needed to edit genomic DNA. Their discovery relies on a protein named Cas9 found in the Streptococcus bacterial "CRISPR" immune system that cooperates with guide RNA and works like scissors. The protein attacks its prey, the DNA of viruses, and slices it up, preventing it from infecting the bacterium. This system was first discovered by Yoshizumi Ishino and colleagues in 1987 and later characterized by Francisco Mojica, but Doudna and Emmanuelle Charpentier showed for the first time that they could use different RNAs to program it to cut and edit different DNAs.

As CRISPR becomes increasingly used to edit multicellular organisms, Doudna continues to be called upon to serve as a thought-leader on the ethics of changing an organism's function using CRISPR technology. Their discovery has since been further developed by many research groups for applications ranging from fundamental cell biology, plant, and animal research to treatments for diseases including sickle cell anemia, cystic fibrosis, Huntington's disease, and HIV. Doudna and several other leading biologists called for a worldwide moratorium on any clinical application of gene editing using CRISPR. Doudna supports the usage of CRISPR in somatic gene editing, gene alterations which do not get passed to the next generation, but not germline gene editing.

The CRISPR system created a new straightforward way to edit DNA and there was a rush to patent the technique. Doudna and UC Berkeley collaborators applied for a patent and so did a group at the Broad Institute affiliated with the Massachusetts Institute of Technology and Harvard. Feng Zhang at the Broad Institute had shown that CRISPR-Cas9 could edit genes in cultured human cells a few months after Doudna and Charpentier published their method. Before the UC Berkeley patent application was decided, a patent was granted to the Broad investigators and UC Berkeley filed a lawsuit against the decision. In 2017, the court decided in favor of the Broad Institute, who claimed that they had initiated the research earliest and had first applied it to human cell engineering thus supporting editing in human cells with evidence but that the UC Berkeley group had only suggested this application. UC Berkeley appealed on grounds that they had clearly discussed and spelled out how to do the application the Broad had pursued. In September 2018, the appeals court decided in favor of the Broad Institute's patent. Meanwhile, UC Berkeley and co-applicants' patent to cover the general technique was also granted. To further cloud the issue, in Europe the claim of the Broad Institute, to have initiated the research first, was disallowed. The rejection was due to a procedural flaw in the application involving a different set of personnel listed in the lawsuit and the patent application, leading to speculation that the UC Berkeley group would prevail in Europe. Doudna cofounded Caribou Biosciences, a company to commercialize CRISPR technology, in 2011. In September 2013, Doudna cofounded Editas Medicine with Zhang and others despite their legal battles, but she quit in June 2014; Charpentier then invited her to join CRISPR Therapeutics, but she declined following the "divorce"-like experience at Editas. Doudna is also a cofounder of Caribou spin-off Intellia Therapeutics and Scribe Therapeutics, which pioneered CasX, a more compact, next-generation Cas9 which can efficiently cut DNA.

In 2017, with Samuel H. Sternberg, she co-authored A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution, a rare case of the first-person account of a major scientific breakthrough, aimed at the general public.

In addition to the CRISPR breakthrough, Doudna has discovered that the hepatitis C virus utilizes an unusual strategy to synthesize viral proteins. This work could lead to new drugs to stop infections without causing harm to the tissues of the body.

"I have so much optimism about what CRISPR can do to help cure unaddressed genetic diseases and improve sustainable agriculture, but I'm also concerned that the benefits of the technology might not reach those who need it most if we're not thoughtful and deliberate about how we develop the technology," Doudna said.

Mammoth Biosciences

In 2017, Doudna co-founded Mammoth Biosciences, a San Francisco-based bioengineering tech startup. Initial funding raised $23 million, with a series B round of funding in 2020 raising $45 million. The business is focused on improving access to bio sensing tests which address "challenges across healthcare, agriculture, environmental monitoring, biodefense, and more."

COVID-19 response

Beginning in March 2020, Doudna organized an effort to use CRISPR-based technologies to address the COVID-19 pandemic along with Dave Savage, Robert Tjian, Fyodor Urnov, Patrick Hsu, and other colleagues at the Innovative Genomics Institute (IGI), where they also created a testing center. This center processed over 500,000 patient samples from UC Berkeley students, staff and faculty as well as members of the surrounding community and farm workers in the Salinas area. Mammoth Biosciences announced a peer-reviewed validation of a rapid, CRISPR-based point of need COVID-19 diagnostic which is faster and less expensive than qRT-PCR based tests.

Other activities

She is also the founder and chair of the governance board of the Innovative Genomics Institute, which she co-founded in 2014. Doudna is also a faculty scientist at Lawrence Berkeley National Laboratory (LBNL), a senior investigator at the Gladstone Institutes, and an adjunct professor of cellular and molecular pharmacology at the University of California, San Francisco (UCSF). In 2025, a new supercomputer named after Doudna was announced for the National Energy Research Scientific Computing Center at LBNL, intended as the successor to the Perlmutter supercomputer.

Doudna is on the scientific advisory boards of the companies that she cofounded, such as Caribou, Intellia, Mammoth, and Scribe; as well as others such as Altos Labs, Isomorphic Labs, Johnson & Johnson, Synthego, Tempus AI, and Welch Foundation. She joined Sixth Street Partners in 2022 as its chief science advisor, to guide investment decisions related to CRISPR.